{"id":"W3182473146","doi":"10.1016/j.clon.2021.06.009","title":"Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort","year":2021,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"Merck; AstraZeneca Canada; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Nivolumab; Discontinuation; Hazard ratio; Internal medicine; Cohort; Adverse effect; Population; Survival analysis; Proportional hazards model; Confidence interval; Oncology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009280771,0.00007734419,0.0007008335,0.0000460672,0.00002220898,0.000003101126,0.00003184957,0.0001626864,0.00002868784],"category_scores_gemma":[0.00141736,0.00006699139,0.0002460965,0.0001073073,0.00005893674,0.00003517552,0.0000141791,0.00009899619,4.129575e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001079792,"about_ca_system_score_gemma":0.0003752937,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000116016,"about_ca_topic_score_gemma":0.001460139,"domain_scores_codex":[0.9986527,0.0001394796,0.0007435821,0.0002339643,0.00009411381,0.000136136],"domain_scores_gemma":[0.9977939,0.001764322,0.0001751765,0.00015153,0.00006685768,0.00004821622],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002141018,0.0003817637,0.9201062,0.00002474423,0.000122968,0.0000136391,0.00002296021,0.000002564377,0.0006541599,0.00004748123,0.00001468917,0.0764678],"study_design_scores_gemma":[0.01717304,0.00123621,0.979761,0.00005906904,0.0001085111,0.000001347074,0.00008437006,0.0002559945,0.0001727878,0.0001006779,0.0009798082,0.00006720071],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956562,0.000317729,0.0002527548,0.002373385,0.0006835603,0.000451368,0.00000733822,0.00001067804,0.0002470041],"genre_scores_gemma":[0.9967541,0.00003719904,0.002303633,0.0005032721,0.00004267679,0.00004457938,0.00009146325,0.000009902526,0.0002131603],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0764006,"threshold_uncertainty_score":0.273183,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05244218482308755,"score_gpt":0.4277913085962518,"score_spread":0.3753491237731643,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}